The HIB19 antibody reacts with human CD19, a 95 kDa glycoprotein which acts as a co-receptor, along with CD21, CD81 and CD225, in support of the functional B cell receptor (BCR). This complex provides antigen-specific recognition and subsequent activation of B cells to proliferate and differentiate into antibody-secreting cells (plasma cells) or memory B cells, which are crucial for secondary antigen encounter. CD19 is a lineage-differentiation marker, as its expression is detectable at the earliest B cell stages, through development, and is finally lost upon transition to mature plasma cells.
The HIB19 antibody is widely used as a phenotypic marker for CD19 expression on B cells, as well as on dendritic cell subsets.
|Name||FITC Anti-Human CD19 (HIB19)|
|Technical Data Sheet||Download TDS|
|Alternative Names||Leu-12, B4|
|Isotype||Mouse IgG1, kappa|
Kroenke MA, Eto D, Locci M, Cho M, Davidson T, Haddad EK, and Crotty S. 2012. J. Immunol. 188: 3734-3744. (Flow cytometry)
So NSY, Ostrowski MA, and Gray-Owen SD. 2012. J. Immunol. 188: 4008-4022. (in vitro cell capture for microscopy)
Zhang L, Yang N, Conejo-Garcia J-R, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, and Coukos G. 2003. Clin. Cancer Res. 9: 264 – 272. (Immunohistochemistry)
Hibe W, Dirnhofer S, Oberwasserlechner F, Eisterer W, Amman K, Schmid T, Hilbe G, Thaler J, and Woll E. 2003. J. Clin. Pathol. 56: 736-741. (Immunohistochemistry – frozen tissues)